Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

NCT05625659 · View on ClinicalTrials.gov ↗

Study Summary

The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Aim 1: To evaluate the performance of CESM compared to DBT at baseline for breast-cancer screening in women with dense breasts. Aim 2: To evaluate the performance of CESM compared to DBT at the 1-year follow up for breast-cancer screening in women with dense breasts.

Conditions Studied

Interventions

  • DIAGNOSTIC_TEST Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)

Study Locations (11)

Florida

  • Boca Raton Regional Hospital - Christine E. Lynn Women's Health and Wellness Institute — Boca Raton
  • Lake Medical Imaging — The Villages

Alabama

  • University of Alabama, Birmingham — Birmingham

Massachusetts

  • Boston Breast Diagnostic Center — Wellesley Hills

Michigan

  • Henry Ford Health — Detroit

New York

  • Memorial Sloan Kettering Cancer Center — New York

North Carolina

  • Carolina Breast Imaging Specialists — Greenville

Pennsylvania

  • Thomas Jefferson University Hospital — Philadelphia

Texas

  • The University of Texas MD Anderson Cancer Center — Houston

Trial Details

FieldValue
Enrollment Target 2,032 participants
Start Date 2023-03-24
Est. Completion 2027-07-31
Phase NA

Sponsor

American College of Radiology

6 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05625659

The ClinicalTrials.gov registry entry for NCT05625659 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 2,032 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is American College of Radiology, which has 6 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention — of which Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05625659 reports 11 study locations spanning 10 distinct geographic areas — top geographies include Florida, Alabama, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05625659 about?

NCT05625659 is a clinical study titled "Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts". The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Ai...

What is the current status of trial NCT05625659?

This trial is currently recruiting. It is a NA study. The enrollment target is 2,032 participants. The study started on 2023-03-24. Estimated completion is 2027-07-31.

What conditions does trial NCT05625659 study?

This clinical trial studies the following conditions: Breast Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05625659?

The interventions under investigation include: Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) (DIAGNOSTIC_TEST). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05625659?

This trial is sponsored by American College of Radiology, which has 6 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05625659 being conducted?

This trial has 11 study locations across Alabama, Florida, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial